Arbutus Biopharma Corp (ABUS) research
Arbutus Biopharma Corp- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $5.01
- As of
Arbutus Biopharma Corp (ABUS): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-21.
As of . Source: SEC EDGAR filings for ABUS. Method and limitations.
Share the ABUS intelligence card
See ABUS live in the terminal
Track ABUS's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live ABUS terminal, freeActive signals for ABUS
- highCONSENSUS_BUY
3 tracked funds increased ABUS this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +809% to ABUS (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +167% to ABUS (2026Q2)
- mediumNEW_POSITION
TWO SIGMA INVESTMENTS, LP new position in ABUS
- highCONSENSUS_BUY
3 tracked funds increased ABUS this 2026Q2, institutional consensus
FREE, NO ACCOUNT
Every signal on ABUS, as it fires
You are seeing 5 of 19 signals recorded on ABUS since 2026-05-16.
The five above all landed on 2026-09-06. The other 14 were recorded on 3 other days. 11 of the 19 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ABUS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 03879J100 · 2026Q2 | $1.9M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 03879J100 · 2026Q2 | $1.8M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 03879J100 · 2026Q2 | $408K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ABUS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ABUS against its peers
ABUS's operating margin of -271.0% ranks in the 44th percentile of 7 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ABUS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 14.1M USD | 58.6M USD | 39 | 8 |
| Operating margin | -271.0% | -98.2% | 44 | 7 |
| Net margin | -237.9% | -101.1% | 44 | 7 |
| Return on equity | -43.7% | -38.3% | 47 | 17 |
Peers (18): KURA, JANX, SVRA, GLUE, MLTX, CRVS, LXRX, SLDB, JBIO, CADL, DSGN, SANA, AVTX, SGP, IMMX, CLYM, TBPH, ARDX. Left out: HELP (period gap), ATTO (no annual filing), ANL (period gap), OBX (no annual filing), APMD (no annual filing), IVA (period gap), SLBT (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ABUS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ABUS signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ABUSand get the insider, 13F, options, and confluence read in one view.